Latest price announcement: Lorlatinib, a new choice for your health!

Lorlatinib is a new generation of ALK (tyrosine kinase) inhibitor that is widely used in the treatment of ALK-positive non-small cell lung cancer (NSCLC). It was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2018, bringing new treatment options to lung cancer patients.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For specific medical insurance reimbursement prices, please consult the local hospital pharmacy. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

This drug is unique in that it is highly selective against multipleALK mutations and other related proteins. Lorlatinib was designed to overcome the resistance issues that may have arisen in previous treatments with some ALK inhibitors, thus showing better efficacy in the face of complex ALK mutation spectrum.

The molecular structure of lorlatinib is complex and exquisite, which provides it with powerful anti-tumor activity. In addition to its high inhibitory effect on ALK, lorlatinib also has the ability to act on multiple proteins such as ROS1, IGF-1R and InsR, which allows it to more comprehensively intervene in the proliferation and survival of cancer cells during treatment.

Clinical trial data show that lorlatinib shows more significant efficacy in first-line treatment compared with traditionalALK inhibitors, such as crizotinib. The results of the CROWN study showed that lorlatinib significantly prolonged progression-free survival (PFS) in ALKpositive NSCLC patients), bringing patients more lasting disease control.

In addition, lorlatinib has been proven to be relatively well tolerated during treatment, and patients are usually better able to adapt to the drug and alleviate some common adverse reactions, such as visual impairment, abnormal liver function, etc.